Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Celcuity Inc. Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer July 18, 2022 From Celcuity Inc. Via AccessWire Exposures Product Safety Tickers CELC Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences May 26, 2022 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates May 16, 2022 From Celcuity Inc. Via AccessWire Exposures Product Safety Tickers CELC Celcuity Inc. Announces $100 Million Private Placement May 16, 2022 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call May 09, 2022 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences April 05, 2022 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates March 23, 2022 From Celcuity Inc. Via AccessWire Exposures Product Safety Tickers CELC Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call March 16, 2022 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity to Participate in the Cowen 42nd Annual Health Care Conference March 02, 2022 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update January 18, 2022 From Celcuity Inc. Via AccessWire Exposures Product Safety Tickers CELC Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium December 10, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers CELC Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium December 02, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development November 29, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial November 15, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers CELC Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences November 09, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 08, 2021 From Celcuity Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Product Safety Tickers CELC Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call October 29, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases October 18, 2021 From Celcuity Inc. Via Business Wire Tickers CELC Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update August 09, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers CELC Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference August 05, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast August 02, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity to Participate in the William Blair Biotech Focus Conference July 08, 2021 From Celcuity Inc. Via AccessWire Tickers CELC Celcuity Announces Pricing of Follow-on Offering June 28, 2021 From Celcuity Inc. Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory Tickers CELC Celcuity Announces Launch of Follow-on Offering June 28, 2021 From Celcuity Inc. Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory Tickers CELC Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations June 09, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers CELC Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update May 10, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers CELC Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast April 26, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Tickers CELC Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling April 12, 2021 From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Tickers CELC Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update April 08, 2021 From Celcuity Inc. Via Business Wire Tickers CELC Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer April 08, 2021 From Celcuity Inc. Via Business Wire Tickers CELC Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.